Masłowska, K.; Redkiewicz, P.; Halik, P.K.; Witkowska, E.; Tymecka, D.; Walczak, R.; Choiński, J.; Misicka, A.; Gniazdowska, E.
Scandium-44 Radiolabeled Peptide and Peptidomimetic Conjugates Targeting Neuropilin-1 Co-Receptor as Potential Tools for Cancer Diagnosis and Anti-Angiogenic Therapy. Biomedicines 2023, 11, 564.
https://doi.org/10.3390/biomedicines11020564
AMA Style
Masłowska K, Redkiewicz P, Halik PK, Witkowska E, Tymecka D, Walczak R, Choiński J, Misicka A, Gniazdowska E.
Scandium-44 Radiolabeled Peptide and Peptidomimetic Conjugates Targeting Neuropilin-1 Co-Receptor as Potential Tools for Cancer Diagnosis and Anti-Angiogenic Therapy. Biomedicines. 2023; 11(2):564.
https://doi.org/10.3390/biomedicines11020564
Chicago/Turabian Style
Masłowska, Katarzyna, Patrycja Redkiewicz, Paweł Krzysztof Halik, Ewa Witkowska, Dagmara Tymecka, Rafał Walczak, Jarosław Choiński, Aleksandra Misicka, and Ewa Gniazdowska.
2023. "Scandium-44 Radiolabeled Peptide and Peptidomimetic Conjugates Targeting Neuropilin-1 Co-Receptor as Potential Tools for Cancer Diagnosis and Anti-Angiogenic Therapy" Biomedicines 11, no. 2: 564.
https://doi.org/10.3390/biomedicines11020564
APA Style
Masłowska, K., Redkiewicz, P., Halik, P. K., Witkowska, E., Tymecka, D., Walczak, R., Choiński, J., Misicka, A., & Gniazdowska, E.
(2023). Scandium-44 Radiolabeled Peptide and Peptidomimetic Conjugates Targeting Neuropilin-1 Co-Receptor as Potential Tools for Cancer Diagnosis and Anti-Angiogenic Therapy. Biomedicines, 11(2), 564.
https://doi.org/10.3390/biomedicines11020564
